NMI TT Pharmaservices establishes new branch in Berlin

The new outstation will provide life science researchers with the company's proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identification projects for industrial clients and academic partners.

The new outstation is located on the Bayer HealthCare campus, within the CoLaborator building that is rented out by Bayer to smaller companies and start-ups. NMI TT Pharmaservices will be using the new and already functional laboratory space to provide life science researchers with its proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identification projects for industrial clients and academic partners alike. In addition, the new office will play a key role for advancing NMI TT Pharmaservices’ market positioning by expanding its business activities beyond the existing well-established customer base.

“We are very excited to start this new phase in our company’s development,” commented Prof. Dr Hugo Hämmerle, CEO of NMI TT GmbH. “We see our expansion to Berlin as a unique opportunity to intensify our business development efforts across the international pharma and biotech market. This move also happens at a particularly promising time in the development of the proteomics field, which we are keen to help drive forward in the years to come, now through both our Reutlingen team and our new Berlin unit.”

“The chances of this new endeavour are manifold,” added Dr Christoph Sachse, Site Head of the NMI TT Berlin operation. “We expect that being closer to the needs of pharma R&D scientists and the lively Berlin biotech community will substantially help us in further developing and in marketing our wide range of contract research offerings, in particular our multiplex protein profiling platform, but also our capabilities in cellular assays and in generating customised cell lines.”